Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study

• Main Authors: Imke H. Bartelink (Author), Pierre M. Bet (Author), Nicolas Widmer (Author), Monia Guidi (Author), Erik Duijvelaar (Author), Bram Grob (Author), Richard Honeywell (Author), Amanda Evelo (Author), Ivo P. E. Tielbeek (Author), Sue D. Snape (Author), Henrike Hamer (Author), Laurent A. Decosterd (Author), Harm Jan Bogaard (Author), Jurjan Aman (Author), Eleonora L. Swart (Author)
• Format: Book
• Published: Wiley, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID‐19). Total (bound + unbound) and unbound imatinib plasma concentrations obtained from 134 patients with...